Abstract:Ulixertinib (BVD-523) is a first-in-class small molecule inhibitor of ERK1/2 currently being investigated in several oncology clinical trials, both as a single agent and in combination with other anti-cancer therapeutics. Palbociclib and ribociclib are FDA approved orally active, potent, and highly selective reversible inhibitors of the CDK4 and CDK6 kinases. As it is well established that ERK activation increases cyclin D levels and entry into the cell cycle, we hypothesized that the combination of ERK1/2 and CDK4/6 inhibition would have synergistic antitumor activity and cause tumor regression in vivo. Initial in vitro work combined ulixertinib with CDK4/6 inhibitors across a small panel of lung cancer cell lines. Cell lines carrying a KRAS mutation were more sensitive to ulixertinib relative to KRAS wild type cell lines based on single agent IC50 values. The single agent IC50 values for the CDK4/6 inhibitors were dependent on whether a metabolic or non-metabolic readout for cell viability was used. The combination interactions across a dose matrix of concentrations were determined by the Loewe Additivity and Bliss Independence models. The results of combining ulixertinib and CDK4/6 inhibitors ranged from additive to potentially synergistic. The combination of ulixertinib and palbociclib was then assessed against four xenograft models representing colorectal, melanoma, and pancreatic tumor types, each harboring an alteration within a component of the MAPK pathway. Palbociclib monotherapy across all models showed limited tumor growth inhibition (TGI) while ulixertinib monotherapy demonstrated modest TGI across all models. The combination groups demonstrated significant responses ranging from 75% - 90% TGIs. All treatment regimens were well tolerated across all models. Downstream assays were completed including reverse phase protein arrays (RPPA). Using RPPA, treatment effects on protein signaling was evaluated in the MAPK family, cell cycle regulation, and other associated feedback and compensatory pathways. Notably, suppression of protein targets downstream of ERK1/2 were seen with both ulixertinib monotherapy and combination therapy. Similarly, the combination therapy group reduced protein levels involved in cell cycle progression, which was not seen in either monotherapy group alone. The efficacy demonstrated with this preclinical work has proven to be translatable to the clinic as the combination of ulixertinib and palbociclib recently achieved MTD in a Phase I trial in advanced solid tumors including pancreatic cancer (NCT 03454035). Citation Format: Caroline M. Emery, Brian Corgiat, Justin Davis, David Sorrell, Mitch Johnson, Brent Kreider, Deborah Knoerzer. Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1057.

Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

Celecoxib Enhances Anticancer Effect of Cisplatin and Induces Anoikis in Osteosarcoma Via PI3K/Akt Pathway.

Increase of Cyclooxygenase-2 Inhibition with Celecoxib Combined with 5-FU Enhances Tumor Cell Apoptosis and Antitumor Efficacy in a Subcutaneous Implantation Tumor Model of Human Colon Cancer

Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study

Efficacy and Safety Profile of Celecoxib for Treating Advanced Cancers: A Meta-Analysis of 11 Randomized Clinical Trials

Parecoxib and 5-Fluorouracil Synergistically Inhibit EMT and Subsequent Metastasis in Colorectal Cancer by Targeting PI3K/Akt/NF-κB Signaling

Effect Of Celecoxib Combined With Chemotherapy Drug On Malignant Biological Behaviors Of Gastric Cancer

Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells

Cyclooxygenase-2 Inhibitor is a Robust Enhancer of Anticancer Agents Against Hepatocellular Carcinoma Multicellular Spheroids

Neural Precursor Cell Expressed, Developmentally Downregulated 8-Activating Enzyme Inhibitor Mln4924 Sensitizes Colorectal Cancer Cells to Oxaliplatin by Inducing Dna Damage, G2 Cell Cycle Arrest and Apoptosis

Abstract 1057: Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models

Synergistic inhibitory effect of erlotinib and celecoxib on the growth of cholangiocarcinoma cells

Selective Cox-2 Inhibitor Celecoxib Induces Epithelial-Mesenchymal Transition in Human Lung Cancer Cells Via Activating MEK-ERK Signaling

Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis

Combined Cetuximab and Celecoxib Treatment Exhibits a Synergistic Anticancer Effect on Human Oral Squamous Cell Carcinoma in Vitro and in Vivo

Celecoxib Enhances the Sensitivity of Non-Small-cell Lung Cancer Cells to Radiation-Induced Apoptosis Through Downregulation of the Akt/mTOR Signaling Pathway and COX-2 Expression

Acetylbritannilactone is a Potent Synergist of Celecoxib to Inhibit Cyclooxygenase‐2 Expression and to Induce Apoptosis in Human Breast Cancer Cells

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.

Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner.